Table 1. Histologic Changes Around End of Implant on Post-Operative Day 12.
Treatment Group | Fibrosis (Masson’s Trichrome) | Cellularity (H&E) |
---|---|---|
S/B/I | + | ++ |
S/I | ++ | ++ |
BSS | +++ | +++ |
MMC | +/- | - |
S/B/I = Saratin/Bevacizumab/Ilomastat; S/I = Saratin/Ilomastat; BSS = Balanced Saline Solution; MMC = Mitomycin-C;– = absent; +/- = weakly present; +, ++, +++ = present in increasing amounts, as graded by the masked observer.